Androgen deprivation therapy prevents bladder cancer recurrence

Koji Izumi, Masataka Taguri, Hiroshi Miyamoto, Yoshinori Hara, Takeshi Kishida, Kimio Chiba, Tetsuo Murai, Kotaro Hirai, Kotaro Suzuki, Kiyoshi Fujinami, Teiichiro Ueki, Koichi Udagawa, Kazuo Kitami, Masatoshi Moriyama, Yasuhide Miyoshi, Futoshi Tsuchiya, Ichiro Ikeda, Kazuki Kobayashi, Maho Sato, Satoshi MoritaKazumi Noguchi, Hiroji Uemura

Research output: Contribution to journalArticle

Abstract

Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients. We retrospectively reviewed 20,328 patients with PC diagnosed during 1991-2013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort. With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17-0.49) for BC recurrence. This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence.

Original languageEnglish (US)
Pages (from-to)12665-12674
Number of pages10
JournalOncotarget
Volume5
Issue number24
DOIs
StatePublished - Jan 1 2014

    Fingerprint

Keywords

  • Androgen
  • Androgen deprivation therapy
  • Bladder cancer
  • Recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

Izumi, K., Taguri, M., Miyamoto, H., Hara, Y., Kishida, T., Chiba, K., Murai, T., Hirai, K., Suzuki, K., Fujinami, K., Ueki, T., Udagawa, K., Kitami, K., Moriyama, M., Miyoshi, Y., Tsuchiya, F., Ikeda, I., Kobayashi, K., Sato, M., ... Uemura, H. (2014). Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget, 5(24), 12665-12674. https://doi.org/10.18632/oncotarget.2851